
Actinium Pharmaceuticals (ATNM) Stock Forecast & Price Target
Actinium Pharmaceuticals (ATNM) Analyst Ratings
Bulls say
Actinium Pharmaceuticals Inc. is experiencing a positive outlook driven by its innovative approach to cancer treatment via its antibody-drug constructs, Iomab-B and Actimab-A, which utilize proprietary technology to target cancer cells directly. Recent preclinical data supporting Actimab-A's ability to selectively deplete myeloid-derived suppressor cells (MDSCs) in solid tumors enhances the anticipated efficacy of existing checkpoint inhibitors, thus de-risking ongoing and future clinical investigations. Furthermore, the initiation of a clinical trial under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute signifies strong strategic partnerships that could lead to significant cost savings and support the advancement of Actinium’s product candidates.
Bears say
Actinium Pharmaceuticals Inc. faces potential setbacks due to the risk of failed or inconclusive clinical trials, which could hinder the development of its key product candidates, Iomab-B and Actimab-A. Additionally, the company's reliance on securing adequate funding to progress these drugs through their development pathway poses a significant financial risk. Despite the presence of a substantial unmet medical need for effective therapies in acute myeloid leukemia (AML), these challenges contribute to a negative outlook for the company's stock performance.
This aggregate rating is based on analysts' research of Actinium Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Actinium Pharmaceuticals (ATNM) Analyst Forecast & Price Prediction
Start investing in Actinium Pharmaceuticals (ATNM)
Order type
Buy in
Order amount
Est. shares
0 shares